Intellectual Product
AstraZeneca Wins Patent Infringement Case Against Pfizer, Vacates $107.5M Jury Award
AstraZeneca, Pfizer, patent infringement, jury award, US court
Novo Nordisk’s Wegovy Approved in China: Implications and Future Challenges
Novo Nordisk, Wegovy, semaglutide, obesity treatment, China approval, generic competition, patent expiration, pharmaceutical market
Metagenomi Shifts Focus from ALS to Kidney Disease, Seeks New Partners
Metagenomi, ALS, kidney disease, gene editing, base editing, RIGS, Metagenomi drops ALS program, new kidney disease partner
Evotec Announces 400 Job Cuts Amid Market Challenges
Evotec, job cuts, market challenges, restructuring, drug discovery, contract development, manufacturing
Metagenomi Halts ALS Research Following Biogen and Ionis Setbacks
Metagenomi, ALS program, Biogen, Ionis, pharmaceutical industry, drug development, layoffs, market challenges
Novo Nordisk Pursues FDA Filing for Once-Weekly Insulin and Semaglutide Combo After Icodec Rejection
Novo Nordisk, insulin icodec, semaglutide, FDA filing, type 2 diabetes, once-weekly insulin, IcoSema, COMBINE-1 study, regulatory approval
Lexicon Pharmaceuticals Reduces Workforce by 50% to Focus on Diabetes Drug
Lexicon Pharmaceuticals, workforce reduction, diabetes drug, restructuring, Zynquista
Novartis Fails to Block MSN’s Entresto Generic Launch
Novartis, Entresto, MSN Pharmaceuticals, generic drugs, patent infringement, FDA approval
Amgen Boosts Full-Year Sales Forecast Following Horizon-Driven Revenue Surge
Amgen, full-year sales forecast, Horizon acquisition, revenue growth, pharmaceutical industry
Madrigal’s MASH Drug Rezdiffra Surpasses Q2 Sales Estimates
Madrigal Pharmaceuticals, Rezdiffra, MASH drug, Q2 earnings, sales estimates, FDA approval, commercial launch, NASH treatment